Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — CRISPR-Cas9 CD33-deleted allogeneic HCT with GO maintenance in AML (PMID 42120728)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First-in-class application of CRISPR antigen deletion to protect a donor graft from post-transplant targeted therapy; platform concept is genuinely transformative |
| Clinical Relevance | 7 | Directly addresses post-HCT relapse in high-risk AML/MDS — a major unmet need — but trial stopped early (n=4 Phase 2), abstract only, 3 TRMs |
| Population Reach | 5 | |
| Implementation Speed | 2 | Gene-edited cell product requires regulatory approval, specialized manufacturing, Phase 2/3 trial completion; 7–10+ years realistic |
| Evidence Strength | 5 | Phase 1/2a, n=30, abstract only, early trial termination, 10% TRM; engraftment endpoint met but efficacy unproven |
Key quantitative result: 30/30 engraftment by Day 28 (median 10 days); GO maintenance tolerated up to 2 mg/m²; 3/30 TRM (10%); 19/30 received GO maintenance.
External validation: None; single-arm, no comparator.
Main limitation: Trial stopped early; Phase 2 expansion enrolled only n=4; no efficacy (OS/PFS) data; abstract only; 10% TRM is clinically significant.
Equity implications: Requires specialized academic HCT centers; likely inaccessible to patients in LMICs or underserved rural settings. Donor matching requirements add complexity for patients from underrepresented ethnic groups with limited donor registries.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 9 | Phase 2 composite: 5.7
Article 2 — Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN) (PMID 42120723)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First Phase 3 RCT establishing oral GLP-1RA as a step-down maintenance strategy after injectable; the concept is anticipated but the evidence is new and directly addresses a critical gap |
| Clinical Relevance | 9 | Directly solves a pressing clinical problem: most patients regain weight after stopping injectable GLP-1RAs; oral maintenance addresses cost, access, and tolerability barriers |
| Population Reach | 9 | Obesity affects >1 billion people globally; injectable GLP-1RA use is expanding rapidly; millions will need a maintenance strategy |
| Implementation Speed | 8 | Orforglipron is in regulatory review; Phase 3b data accelerates label expansion discussions; oral formulation removes cold-chain barriers; 1–3 years plausible |
| Evidence Strength | 8 | Phase 3b double-blind RCT, two cohorts, all secondary endpoints met, strong effect sizes (treatment differences 25.5–41.7%); industry-funded but robust design |
Key quantitative result: Orforglipron maintained 74.7% (post-tirzepatide) and 79.3% (post-semaglutide) of prior weight reduction vs 49.2% and 37.6% with placebo (both P<0.001); treatment differences of 25.5% and 41.7%.
External validation: Not independently replicated; single sponsor trial; companion to SURMOUNT-5 participants provides some continuity context.
Main limitation: Abstract only; 52-week data only; unclear long-term durability beyond the trial window; industry-funded (Eli Lilly); no head-to-head with continued injectable therapy.
Equity implications: Oral formulation is a major equity win — removes injection training burden, cold-chain requirements, and some cost barriers vs. injectables. However, cost of orforglipron itself will determine real-world access, particularly in LMICs and for uninsured patients. Does not yet include diverse populations with adequate reporting.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 9 | Phase 2 composite: 8.3
Article 3 — Unprocessed U1 snRNAs as a biomarker of INTS11- and BRAT1-related neurodevelopmental disorders (PMID 42116163)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First demonstration that BRAT1 mutations impair Integrator-mediated U1 snRNA processing; redefines BRAT1 disease as an Integrator disorder; opens new mechanistic pathway |
| Clinical Relevance | 7 | Directly enables variant reclassification for VUS-level BRAT1 diagnoses and introduces a quantitative severity biomarker; no treatment exists, but diagnostic clarity has immediate clinical utility |
| Population Reach | 4 | Ultra-rare disorders; absolute patient numbers are very small globally (~hundreds to low thousands known), but within this population unmet need is extreme and the biomarker is immediately applicable |
| Implementation Speed | 4 | Cell-based assay (fibroblasts/LCLs) requires clinical laboratory development and validation; could be implemented in specialized centers within 2–4 years; not yet widely available |
| Evidence Strength | 7 | Multi-institutional cohort + functional zebrafish validation + correlation of biomarker magnitude with clinical severity; Genome Medicine; patient cohort size unspecified but multi-site authorship; mixed species model appropriately caps ceiling |
Key quantitative result: U1 snRNA misprocessing magnitude correlates with clinical severity across BRAT1 patient cohort (quantitative correlation described; specific metrics not extractable from abstract).
External validation: Zebrafish knockout model independently recapitulates phenotype, providing orthogonal mechanistic validation.
Main limitation: Patient cohort size not reported in abstract; mixed-species model; abstract only; COI (zebrafish tools company co-founder among authors). Not therapeutic — biomarker only.
Equity implications: Rare disease diagnostics disproportionately help patients in high-resource settings who can access genomic testing. International authorship (UCL, Prague, Cairo, Bergen) is notable and may increase global accessibility of the assay. Families receiving VUS-level diagnoses — often in underserved diagnostic settings — are the primary beneficiaries.
Evidence Maturity: Validated ✓ (confirmed, with caveat: cohort size unspecified)
Triage score (OpenClaw): 9 | Phase 2 composite: 6.3
Article 4 — Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated GBM (PMID 42120910)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First DNA-based personalized vaccine encoding up to 40 neoantigens/patient in GBM; prior peptide vaccines exist but this multi-antigen DNA platform is a step change |
| Clinical Relevance | 6 | MGMT unmethylated GBM has median OS ~12–18 months with SOC; met pre-specified endpoints; 4-year survivor; but n=9 with no comparator arm |
| Population Reach | 4 | ~13,000 new GBM cases/year in US; MGMT unmethylated = ~60%, so ~7,800/year; extremely high unmet need within this group |
| Implementation Speed | 2 | Personalized manufacturing per patient, Phase 2 needed, regulatory pathway complex; 7–10 years minimum |
| Evidence Strength | 5 | Phase 1, n=9, single-arm, no comparator; Nature Cancer publication adds credibility but design inherently limited; abstract only |
Key quantitative result: 6-month PFS 66.7%; 12-month OS 66.7%; median PFS 8.5 months; median OS 16.3 months; 24-month survival 33%; 4-year survivor (1/9); T cell expansion in 8/9.
External validation: None; single-institution Phase 1.
Main limitation: n=9, no control arm, single-arm Phase 1, abstract only; survival endpoints not directly comparable to historical controls without adjustment; 1 patient excluded from immunogenicity analysis due to dexamethasone use.
Equity implications: Personalized manufacturing makes this prohibitively expensive for most patients globally. High-income academic center access only for foreseeable future. GBM affects all demographics; cost equity is the dominant barrier.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 8 | Phase 2 composite: 4.9
Article 5 — Pasteurized Akkermansia muciniphila MucT for weight loss maintenance (PMID 42120725)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First human RCT of pasteurized A. muciniphila as weight maintenance intervention; novel microbiome-pharmacology; mechanism distinct from all existing pharmacological approaches |
| Clinical Relevance | 7 | Addresses weight regain — the central challenge in obesity management — with a non-drug, orally administered, safe supplement; complements GLP-1RA landscape |
| Population Reach | 8 | Obesity affects >1 billion people; this intervention targets the weight maintenance phase after dietary weight loss, a near-universal challenge |
| Implementation Speed | 7 | Pasteurized supplement = no live organism regulatory hurdles; regulatory pathway faster than drug; 2–4 years plausible if larger trials confirm; already commercially available in some markets as supplement |
| Evidence Strength | 7 | RCT, n=90, pre-specified primary endpoint met, significant effect sizes, safe profile; 24-week maintenance window is relatively short; industry COI but design is sound |
Key quantitative result: 1.2±0.7 kg regain (MucT) vs 3.2±0.4 kg (placebo), P=0.012; net weight loss from baseline 3.1±0.7 kg MucT vs placebo (P=0.009).
External validation: Not independently replicated; first RCT of this specific formulation.
Main limitation: n=90, 24-week only, abstract only; industry COI (CTO of The Akkermansia Company among authors); no comparison with GLP-1RA step-down or other maintenance strategies.
Equity implications: Supplement formulation (if accessible) could be considerably cheaper than pharmaceutical GLP-1RAs. Baseline Akkermansia abundance as predictor of response may create biomarker-stratified access considerations. Global availability and affordability of clinical-grade pasteurized formulation unclear.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 8 | Phase 2 composite: 7.5
Article 6 — SPECTRAL photonic hydrogel platform for cancer prediction (PMID 42116274)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Highly novel integrated platform (photonic crystal hydrogel + PNA probes + ML) detecting 205 ctDNA mutations + 8 proteins simultaneously, sequencing-free |
| Clinical Relevance | 4 | Early feasibility; sample size undisclosed; three cancer types only; no head-to-head vs. approved liquid biopsy methods |
| Population Reach | 7 | Multi-cancer liquid biopsy applicable to lung, breast, colorectal cancer populations (hundreds of millions globally); democratization potential if validated |
| Implementation Speed | 2 | Preclinical feasibility stage; requires large prospective validation, regulatory approval, manufacturing scale-up; 8–12 years realistic |
| Evidence Strength | 3 | Classification confidence medium; sample size not disclosed; single-site feasibility study; no comparator; abstract only |
Key quantitative result: 90.0% specificity, 86.7% sensitivity, 87.5% overall accuracy across three cancer types.
External validation: None.
Main limitation: Sample size not disclosed; no comparator; single platform validation study; medium classification confidence.
Equity implications: Low-cost, sequencing-free platform design has strong equity potential for LMICs where sequencing infrastructure is limited — but validation and regulatory approval will favor high-income markets first.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 4.5
Article 7 — NUP98-rearranged AML mutational profiling and outcomes (PMID 42120929)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Largest adult NUP98r AML cohort; confirms and extends existing knowledge but not mechanistically novel |
| Clinical Relevance | 7 | Actionable: FLT3i use and HSCT independently improve survival; 53.3% 5-year OS with FLT3i is clinically meaningful in this adverse-risk group |
| Population Reach | 4 | NUP98r AML is ~3–5% of adult AML; small absolute numbers but high unmet need |
| Implementation Speed | 7 | FLT3 inhibitors are already approved; this study supports their use in NUP98r/FLT3-ITD patients; implementable with existing drugs |
| Evidence Strength | 6 | Retrospective multicenter cohort, n=95; largest adult series; no randomization; retrospective design limits causal inference |
Key quantitative result: Median OS 15.2 months overall; FLT3i-treated: median OS not reached, 5-year OS 53.3%; NUP98::NSD1 most common (54%).
External validation: Multicenter (French network) adds some validation; no independent external cohort.
Main limitation: Retrospective; no randomization; abstract only; no propensity adjustment described; historical treatment heterogeneity.
Equity implications: NUP98r AML disproportionately affects younger adults; access to FLT3 inhibitors varies by geography and insurance status. Patients in LMICs may lack access to these agents.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 5.8
Article 8 — BTKi vs VenR in second-line CLL: Czech real-world analysis (PMID 42120657)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Confirms similar efficacy already suggested by cross-trial comparisons; novel as first direct real-world comparison |
| Clinical Relevance | 7 | Directly informs treatment selection between two standard-of-care options; BTKi infection signal is actionable |
| Population Reach | 5 | CLL affects ~200,000 patients in US; second-line setting is a meaningful subset; globally relevant |
| Implementation Speed | 8 | Both agents are approved and in current use; findings immediately applicable to treatment selection counseling |
| Evidence Strength | 6 | Real-world retrospective cohort, n=352; largest direct comparison dataset; baseline imbalances not fully controlled; no propensity matching |
Key quantitative result: 12-month PFS 82.2% vs 85.1% (p=0.265); OS 88.4% vs 87.6% (p=0.291); BTKi discontinuation 34.3% vs 22.5% (infection-driven).
External validation: Single-country (Czech) data; not independently replicated.
Main limitation: Retrospective; baseline imbalances (higher TP53 mutation in BTKi group); no propensity matching; Czech healthcare context may limit generalizability.
Equity implications: Fixed-duration VenR may be preferable in lower-resource settings given finite treatment duration and potentially lower long-term cost. BTKi infection risk is disproportionate in immunocompromised and older patients.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 5.9
Article 9 — Single-cell mechanodeformation signatures in hematologic malignancies (review) (PMID 42118701)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Label-free biomechanical profiling is a genuinely novel diagnostic modality; review synthesizes emerging evidence |
| Clinical Relevance | 4 | No direct patient care change currently; clinical readiness not established; multi-site validation pending |
| Population Reach | 6 | Leukemias and myeloma affect hundreds of thousands; label-free approach could be additive to existing diagnostics |
| Implementation Speed | 2 | Technology not yet validated at multi-site scale; standardization and harmonization needed |
| Evidence Strength | 2 | Review article; no primary data; design quality inherently limited |
Main limitation: Review only; no original data; multi-site validation is the explicit gap.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.0
Article 10 — Immunopeptidomics with liquid biopsy for precision oncology (review) (PMID 42119346)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Integration of immunopeptidomics with liquid biopsy is a forward-looking conceptual advance; some methodological novelty |
| Clinical Relevance | 3 | Conceptual review only; no clinical data; years from patient impact |
| Population Reach | 6 | If realized, applicable to all solid tumor immunotherapy candidates |
| Implementation Speed | 1 | Very early conceptual stage; technical barriers are substantial |
| Evidence Strength | 2 | Narrative review; no primary data |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.5
Article 11 — ctDNA limited utility in pseudomyxoma peritonei (PMID 42119195)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Negative finding in a rare context; limited mechanistic novelty but clinically informative |
| Clinical Relevance | 6 | Important negative result: prevents misallocation of resources toward ctDNA monitoring in PMP; redirects surveillance strategy |
| Population Reach | 2 | PMP is very rare (~2–4 per million/year); limited absolute reach |
| Implementation Speed | 7 | Immediately actionable: informs against adopting ctDNA monitoring in PMP management |
| Evidence Strength | 6 | Prospective cohort, n=95, ddPCR methodology; reasonable design for this rare condition |
Key quantitative result: ctDNA detected in only 8/95 (8%) patients; median mutated allele frequency 0.1.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.7
Article 12 — Peripheral retinal haemorrhage density on UWF imaging for DR progression (PMID 42120190)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Peripheral UWF biomarkers are an emerging area; AI-quantification of haemorrhage density as specific predictor adds to existing knowledge |
| Clinical Relevance | 7 | Directly identifies high-risk patients for intensified surveillance; potentially changes DR screening protocols |
| Population Reach | 8 | ~537 million people with diabetes globally; DR is the leading cause of preventable blindness; peripheral imaging biomarkers applicable broadly |
| Implementation Speed | 7 | UWF imaging already in use at many eye centers; AI quantification tools are commercially available; near-term implementation feasible |
| Evidence Strength | 7 | Prospective 2-year longitudinal, n=528 eyes, multiethnic Asian cohort; independent OR calculations; robust design |
Key quantitative result: Peripheral haemorrhage density OR=3.09 (p=0.044); PPL OR=4.00 (p=0.040); 1.6× higher progression risk for PPLs.
External validation: Single-center (Singapore); multi-ethnic within cohort but not independently externally validated.
Main limitation: Single-center; Asian cohort only; 2-year window may miss later progressors; abstract only.
Equity implications: AI-UWF tools require upfront capital; may be unavailable in primary care diabetes clinics in LMICs. Singapore cohort may not generalize to all ethnic groups or healthcare systems.
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 7.0
Article 13 — SHAP-interpretable ML model for stroke risk using serum miRNAs (PMID 42120650)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Interpretable ML + miRNA biomarkers is a familiar combination; SHAP application is incremental |
| Clinical Relevance | 4 | AUC 1.0 on training strongly suggests overfitting; external validation n=10 is insufficient |
| Population Reach | 7 | Stroke is the second leading cause of death globally; risk prediction tools have massive potential reach |
| Implementation Speed | 2 | Requires large prospective validation before any clinical use; external cohort of n=10 is not validation |
| Evidence Strength | 2 | Perfect training AUC = high overfitting probability; n=10 external validation is critically insufficient; medium classification confidence |
Main limitation: AUC 1.0 is a red flag for overfitting; external validation n=10 is scientifically inadequate for generalizability claims.
Evidence Maturity: Exploratory ✓ (confirmed; flagging concern about overfitting)
Triage score (OpenClaw): 6 | Phase 2 composite: 3.7
Article 14 — Single-cell impedance sensing chip for intraoperative tumor diagnosis (PMID 42120887)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | $1 semiconductor chip for 20-minute intraoperative differentiation is technically novel and cost-disruptive |
| Clinical Relevance | 5 | Intraoperative decision-making is a real clinical need; but sample size undisclosed, feasibility only |
| Population Reach | 7 | Applicable across 6 tumor types; intraoperative pathology is a universal surgical need |
| Implementation Speed | 3 | Requires clinical validation, regulatory approval, integration into surgical workflow; 5–8 years realistic |
| Evidence Strength | 3 | Feasibility study; sample size not disclosed; medium confidence; abstract only |
Main limitation: Sample size undisclosed; no sensitivity/specificity reported from abstract; single-institution feasibility.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.9
Article 15 — SERS + AI for CKD early diagnosis using serum KIM-1 (PMID 42120702)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SERS + XGBoost combination for KIM-1 is a technically novel biosensor approach |
| Clinical Relevance | 5 | CKD early detection is clinically important; but sample size and prospective validation absent |
| Population Reach | 8 | ~850 million people with CKD globally; early detection biomarkers have enormous potential reach |
| Implementation Speed | 3 | POC potential but requires prospective validation, regulatory approval |
| Evidence Strength | 2 | Sample size not disclosed; no prospective validation described; LOOCV only; medium confidence |
Main limitation: Sample size absent; no prospective cohort; 98.42% accuracy claims require external validation.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.5
Article 16 — MILA-MIL: Mamba-inspired linear attention for WSI survival prediction (PMID 42118628)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-branch Mamba-inspired architecture is architecturally novel within the MIL WSI space |
| Clinical Relevance | 4 | Computational pathology tool; no direct clinical validation; benchmark improvement over existing methods |
| Population Reach | 6 | Six diverse cancer cohorts; potentially applicable across oncology |
| Implementation Speed | 3 | Research-grade tool; requires clinical integration, prospective validation, EHR embedding |
| Evidence Strength | 5 | Multi-cohort computational validation; no prospective clinical outcome data; benchmark comparisons only |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 4.8
Article 17 — NSCLC blood proteomics: surgical and immunotherapeutic responses (PMID 42120924)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Dual-platform (7596 + 250 proteins) multi-timepoint discovery with cross-platform validation is technically rigorous and incremental in novelty |
| Clinical Relevance | 5 | ICI response prediction and recurrence biomarkers are clinically relevant; but n=56, discovery-stage only |
| Population Reach | 7 | NSCLC is the most common cancer death globally; ICI response prediction has broad applicability |
| Implementation Speed | 3 | Biomarker discovery; requires prospective validation in larger cohorts before clinical use |
| Evidence Strength | 6 | Prospective multi-timepoint; dual-platform cross-validation; n=56 limits power; industry COI |
Key quantitative result: Lower baseline IL-6, CCL19, SPP1, PDCD1 in ICI responders; MUC16, IL36G, COX7A2L as recurrence signatures; validated by nELISA.
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 7 | Phase 2 composite: 5.3
Article 18 — CM-LP11 methylation biomarker for cutaneous melanoma prognosis (PMID 42118848)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Lactylation-related methylation as a prognostic model is a novel biological angle; relative methylation ordering approach is methodologically interesting |
| Clinical Relevance | 4 | Multi-cohort validation, but bioinformatics only; prospective clinical utility unproven |
| Population Reach | 5 | ~325,000 melanoma cases/year globally; TCGA training limits generalizability |
| Implementation Speed | 3 | Methylation profiling already available; but prospective validation and clinical integration needed |
| Evidence Strength | 5 | Three cohorts (n=699 total); retrospective; TCGA training set has well-known biases |
Evidence Maturity: Exploratory ✓ (confirmed; publication date placeholder noted)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.5
Article 19 — Feladilimab + docetaxel vs docetaxel in NSCLC (ENTRÉE Lung Sub-study 1) (PMID 42120929)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Negative ICOS agonist trial; confirms a hypothesis rather than disproving a known mechanism |
| Clinical Relevance | 7 | Negative RCT results have direct and immediate clinical relevance; closes off a development pathway |
| Population Reach | 6 | Advanced NSCLC post-checkpoint progression is a large, growing population globally |
| Implementation Speed | 8 | Negative result is immediately actionable — clinicians and sponsors can deprioritize this approach |
| Evidence Strength | 6 | Phase 2 RCT, n=105, randomized, platform design; open-label; underpowered for definitive conclusions |
Key quantitative result: OS HR 1.5 (95% CI 0.92–2.44); OS 7.8 vs 8.2 months; ORR 19% vs 11%.
Evidence Maturity: Validated ✓ (confirmed — negative finding is validated evidence)
Triage score (OpenClaw): 5 | Phase 2 composite: 5.9
Article 20 — FMISO PET changes as ICI response predictors in NSCLC (pilot) (PMID 42120578)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Hypoxia PET as dynamic ICI response monitor is novel; FMISO-PET in NSCLC ICI context is original |
| Clinical Relevance | 4 | n=17 pilot only; hypothesis-generating; insufficient for practice guidance |
| Population Reach | 6 | NSCLC ICI patients are a large population; PET response monitoring would be broadly applicable if validated |
| Implementation Speed | 2 | FMISO-PET is not routinely available; requires prospective trial before clinical use |
| Evidence Strength | 3 | n=17 pilot; no control arm; medium confidence; exploratory only |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 4.2
Article 21 — Alloantigen-expressing virotherapy for PDAC (preclinical) (PMID 42120181)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Exploiting MHC alloantigen mismatch rejection mechanisms to convert immune-cold PDAC is mechanistically creative and highly original |
| Clinical Relevance | 3 | Preclinical only; Clinical Relevance capped at 5 per non-human model rule; current data insufficient for clinical extrapolation |
| Population Reach | 5 | Pancreatic cancer kills ~50,000 in US/year; deeply unmet need; high reach relative to disease burden |
| Implementation Speed | 1 | Mouse model only; first-in-human trials likely 5–8+ years away |
| Evidence Strength | 4 | Two immunocompetent mouse PDAC models; rechallenge survival data; JITC publication; non-human cap applies |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.9
Article 22 — Healthcare costs of four obesity medications (real-world claims) (PMID 42120922)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | GLP-1RA cost burden is well-recognized; this study adds quantification with a large dataset but does not include newer weekly agents |
| Clinical Relevance | 6 | Directly relevant to formulary decisions and policy; liraglutide data is partially outdated but cost structure findings are informative |
| Population Reach | 9 | Obesity is a global epidemic; n=228,654 is a massive dataset; cost data affects coverage policies affecting millions |
| Implementation Speed | 7 | Findings immediately relevant to payers, policymakers, and prescribers |
| Evidence Strength | 6 | Very large retrospective claims study; includes only older agents (pre-semaglutide/tirzepatide); commercial claims only |
Key quantitative result: Liraglutide total costs 73.6% higher in year 1 vs phentermine; no favorable utilization changes to offset cost.
Main limitation: Pre-dates semaglutide and tirzepatide; commercial insurance only (excludes Medicaid/uninsured populations).
Evidence Maturity: Validated ✓ (confirmed, with caveat about drug vintage)
Triage score (OpenClaw): 6 | Phase 2 composite: 6.1
Article 23 — Prepregnancy GLP-1RA exposure and hypertensive disorders of pregnancy (PMID 42120704)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | GLP-1RA prepregnancy safety in obese/diabetic women is a clinically urgent and understudied area |
| Clinical Relevance | 6 | Safety signal for preeclampsia in a growing real-world exposure scenario; but n=31 exposed is critically small |
| Population Reach | 7 | Millions of reproductive-age women are now prescribed GLP-1RAs; safety data during pregnancy is a major knowledge gap |
| Implementation Speed | 5 | Signal warrants clinical attention but cannot change guidelines without larger data; immediate utility is awareness-raising |
| Evidence Strength | 2 | n=31 exposed; retrospective EHR; propensity-matched but underpowered; medium confidence |
Main limitation: n=31 exposed — severely underpowered; observational; confounding by indication likely.
Evidence Maturity: Exploratory ✓ (confirmed; hypothesis-generating only)
Triage score (OpenClaw): 5 | Phase 2 composite: 5.3
Article 24 — Caring role and cognitive function trajectory in later life (ELSA) (PMID 42120013)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Caring role as bidirectional cognitive modifier is a novel angle; large longitudinal study adds empirical weight |
| Clinical Relevance | 5 | Relevant to carer support policy and geriatric medicine; no direct treatment implication |
| Population Reach | 7 | ~53 million informal carers in the US; aging globally; this affects a massive population |
| Implementation Speed | 6 | Policy and carer support interventions are addressable without new technology; findings translatable to public health guidance |
| Evidence Strength | 7 | ELSA longitudinal (19 years, n=5530 matched), propensity-matching, robust design |
Evidence Maturity: Validated ✓ (confirmed)
Triage score (OpenClaw): 6 | Phase 2 composite: 5.9
Article 25 — Gut microbiota remodeling during aging (review) (PMID 42118429)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Reviews well-established aging-microbiome literature; primarily a synthesis |
| Clinical Relevance | 3 | Review only; no new clinical data |
| Population Reach | 7 | Universal aging population relevance |
| Implementation Speed | 2 | Conceptual review; no near-term clinical translation |
| Evidence Strength | 2 | Narrative review; no primary data |
Evidence Maturity: Exploratory ✓ (confirmed)
Triage score (OpenClaw): 5 | Phase 2 composite: 3.6
PHASE 3 — Ranking
Conflicting Evidence Notes
GLP-1RA landscape (Articles 2, 5, 22, 23): These four articles present a nuanced and partially conflicting picture of GLP-1RA therapy. Article 2 (orforglipron) establishes a strong pharmacological maintenance strategy; Article 5 (Akkermansia) offers a non-pharmacological complement; Article 22 raises legitimate cost-effectiveness concerns for older agents that likely extrapolate to newer ones; and Article 23 introduces an important but unconfirmed safety signal in pregnancy. Together, they reinforce clinical efficacy but underscore unresolved questions around cost, long-term access, and reproductive safety that practitioners must weigh.
Composite Impact Score Calculation
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| # | Article (PMID) | Clin Rel | Pop Reach | Sci Nov | Impl Speed | Evid Str | Impact Score | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Orforglipron ATTAIN-MAINTAIN (42120723) | 9 | 9 | 7 | 8 | 8 | 8.40 | 9 | 🟢 |
| 2 | Akkermansia MucT RCT (42120725) | 7 | 8 | 8 | 7 | 7 | 7.50 | 8 | 🟠 |
| 3 | Peripheral UWF DR prediction (42120190) | 7 | 8 | 6 | 7 | 7 | 7.10 | 7 | 🟢 |
| 4 | BRAT1/INTS11 U1 snRNA biomarker (42116163) | 7 | 4 | 9 | 4 | 7 | 6.30 | 9 | 🟡 |
| 5 | CRISPR CD33 allo-HCT trem-cel (42120728) | 7 | 5 | 9 | 2 | 5 | 5.70 | 9 | 🟠 |
| 6 | NUP98r AML outcomes + FLT3i (42120929) | 7 | 4 | 5 | 7 | 6 | 5.80 | 7 | ⬜ |
| 7 | Feladilimab NSCLC (negative RCT) (42120929) | 7 | 6 | 4 | 8 | 6 | 5.90 | 5 | ⬜ |
| 8 | BTKi vs VenR CLL real-world (42120657) | 7 | 5 | 4 | 8 | 6 | 5.90 | 6 | 🟢 |
| 9 | Obesity medication costs (42120922) | 6 | 9 | 4 | 7 | 6 | 6.10 | 6 | ⬜ |
| 10 | GBM neoantigen DNA vaccine (42120910) | 6 | 4 | 8 | 2 | 5 | 4.90 | 8 | 🟠 |
| 11 | Prepregnancy GLP-1RA safety (42120704) | 6 | 7 | 6 | 5 | 2 | 5.30 | 5 | 🟡 |
| 12 | NSCLC blood proteomics (42120924) | 5 | 7 | 6 | 3 | 6 | 5.30 | 7 | ⬜ |
| 13 | ELSA caring role + cognition (42120013) | 5 | 7 | 5 | 6 | 7 | 5.90 | 6 | ⬜ |
| 14 | SPECTRAL ctDNA platform (42116274) | 4 | 7 | 8 | 2 | 3 | 4.50 | 7 | 🔴 |
| 15 | PMP ctDNA negative finding (42119195) | 6 | 2 | 4 | 7 | 6 | 4.70 | 5 | ⬜ |
| 16 | CKD SERS+AI KIM-1 (42120702) | 5 | 8 | 6 | 3 | 2 | 4.50 | 6 | ⬜ |
| 17 | IC-ECIS chip intraoperative (42120887) | 5 | 7 | 7 | 3 | 3 | 4.90 | 6 | ⚪ |
| 18 | PDAC alloantigen virotherapy (42120181) | 3 | 5 | 8 | 1 | 4 | 3.90 | 5 | ⚪ |
| 19 | Mechanodeformation review (42118701) | 4 | 6 | 6 | 2 | 2 | 4.00 | 5 | ⚪ |
| 20 | FMISO PET ICI pilot (42120578) | 4 | 6 | 6 | 2 | 3 | 4.20 | 5 | ⚪ |
| 21 | MILA-MIL WSI survival (42118628) | 4 | 6 | 6 | 3 | 5 | 4.80 | 6 | ⬜ |
| 22 | Melanoma CM-LP11 methylation (42118848) | 4 | 5 | 6 | 3 | 5 | 4.50 | 5 | ⬜ |
| 23 | Immunopeptidomics + liquid biopsy review (42119346) | 3 | 6 | 6 | 1 | 2 | 3.50 | 5 | ⬜ |
| 24 | Gut microbiota aging review (42118429) | 3 | 7 | 4 | 2 | 2 | 3.60 | 5 | ⬜ |
| 25 | Stroke miRNA ML model (42120650) | 4 | 7 | 5 | 2 | 2 | 3.70 | 6 | ⬜ |
Note on Articles 6/7 PMID collision: The JSON batch assigns PMID 42120929 to both Article 7 (NUP98r AML) and Article 19 (ENTRÉE feladilimab). I have scored them independently per their respective metadata; the PMID collision appears to be a batch error. Article 11 (PMP ctDNA) DOI is also listed identically to SPECTRAL — DOI likely reflects an entry error in the source batch; articles scored per their individual metadata.
Final Ranked Table
| Rank | Article | Impact Score | Clin Rel | Pop Reach | Sci Nov | Impl Speed | Evid Str | Triage Score | Design | Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Orforglipron ATTAIN-MAINTAIN (PMID 42120723) | 8.40 | 9 | 9 | 7 | 8 | 8 | 9 | Phase 3b RCT | 🟢 |
| 2 | Akkermansia MucT RCT (PMID 42120725) | 7.50 | 7 | 8 | 8 | 7 | 7 | 8 | RCT | 🟠 |
| 3 | Peripheral UWF DR prediction (PMID 42120190) | 7.10 | 7 | 8 | 6 | 7 | 7 | 7 | Prospective longitudinal | 🟢 |
| 4 | NUP98r AML outcomes + FLT3i (PMID 42120929) | 5.90 | 7 | 4 | 5 | 7 | 6 | 7 | Retrospective multicenter cohort | ⬜ |
| 4 | Feladilimab NSCLC negative RCT (PMID 42120929) | 5.90 | 7 | 6 | 4 | 8 | 6 | 5 | Phase 2 RCT | ⬜ |
| 4 | BTKi vs VenR CLL (PMID 42120657) | 5.90 | 7 | 5 | 4 | 8 | 6 | 6 | Retrospective real-world cohort | 🟢 |
| 4 | ELSA caring role + cognition (PMID 42120013) | 5.90 | 5 | 7 | 5 | 6 | 7 | 6 | Longitudinal matched cohort | ⬜ |
| 5 | BRAT1/INTS11 U1 snRNA biomarker (PMID 42116163) | 6.30 | 7 | 4 | 9 | 4 | 7 | 9 | Multi-patient biomarker validation | 🟡 |
| 6 | Obesity medication costs (PMID 42120922) | 6.10 | 6 | 9 | 4 | 7 | 6 | 6 | Retrospective claims cohort | ⬜ |
| 7 | CRISPR CD33 allo-HCT trem-cel (PMID 42120728) | 5.70 | 7 | 5 | 9 | 2 | 5 | 9 | Phase 1/2a multicenter | 🟠 |
| 8 | Prepregnancy GLP-1RA safety (PMID 42120704) | 5.30 | 6 | 7 | 6 | 5 | 2 | 5 | Retrospective matched cohort | 🟡 |
| 8 | NSCLC blood proteomics (PMID 42120924) | 5.30 | 5 | 7 | 6 | 3 | 6 | 7 | Prospective biomarker discovery | ⬜ |
| 9 | GBM neoantigen DNA vaccine (PMID 42120910) | 4.90 | 6 | 4 | 8 | 2 | 5 | 8 | Phase 1 single-arm | 🟠 |
| 9 | IC-ECIS intraoperative chip (PMID 42120887) | 4.90 | 5 | 7 | 7 | 3 | 3 | 6 | Device feasibility | ⚪ |
| 10 | MILA-MIL WSI survival (PMID 42118628) | 4.80 | 4 | 6 | 6 | 3 | 5 | 6 | Computational multi-cohort | ⬜ |
| 11 | PMP ctDNA negative finding (PMID 42119195) | 4.70 | 6 | 2 | 4 | 7 | 6 | 5 | Prospective cohort | ⬜ |
| 12 | SPECTRAL ctDNA platform (PMID 42116274) | 4.50 | 4 | 7 | 8 | 2 | 3 | 7 | Analytical feasibility | 🔴 |
| 12 | CKD SERS+AI KIM-1 (PMID 42120702) | 4.50 | 5 | 8 | 6 | 3 | 2 | 6 | Diagnostic accuracy study | ⬜ |
| 12 | Melanoma CM-LP11 methylation (PMID 42118848) | 4.50 | 4 | 5 | 6 | 3 | 5 | 5 | Retrospective bioinformatics | ⬜ |
| 13 | FMISO PET ICI pilot (PMID 42120578) | 4.20 | 4 | 6 | 6 | 2 | 3 | 5 | Pilot prospective | ⚪ |
| 14 | Mechanodeformation review (PMID 42118701) | 4.00 | 4 | 6 | 6 | 2 | 2 | 5 | Review | ⚪ |
| 15 | PDAC alloantigen virotherapy (PMID 42120181) | 3.90 | 3 | 5 | 8 | 1 | 4 | 5 | Preclinical | ⚪ |
| 16 | Stroke miRNA ML model (PMID 42120650) | 3.70 | 4 | 7 | 5 | 2 | 2 | 6 | ML development | ⬜ |
| 17 | Gut microbiota aging review (PMID 42118429) | 3.60 | 3 | 7 | 4 | 2 | 2 | 5 | Narrative review | ⬜ |
| 18 | Immunopeptidomics + liquid biopsy review (PMID 42119346) | 3.50 | 3 | 6 | 6 | 1 | 2 | 5 | Narrative review | ⬜ |
Rank Justifications
🥇 Rank 1 — Orforglipron ATTAIN-MAINTAIN (Impact: 8.40) This Phase 3b double-blind RCT directly and credibly addresses one of the most pressing unresolved problems in obesity medicine: weight regain after stopping injectable GLP-1RA therapy. With treatment differences of 25.5–41.7% in weight maintenance over 52 weeks across two independent cohorts, all secondary endpoints met, and an oral formulation that dramatically lowers administration barriers, this study has a realistic near-term regulatory and implementation pathway. It joins a transformative class of obesity medicines at a time when hundreds of millions globally need a sustainable, accessible maintenance strategy. The combination of high evidence strength (Phase 3b RCT), massive population relevance, and near-term implementability distinguishes this article from all others in this batch.
Why it matters: For the first time, a single daily oral pill has been shown in a rigorous trial to preserve most of the weight lost on an injectable — potentially making the benefits of GLP-1RA therapy sustainable and globally scalable.
🥈 Rank 2 — Akkermansia muciniphila MucT RCT (Impact: 7.50) The first RCT of a pasteurized gut bacterial supplement for weight maintenance reaches statistical significance on its primary endpoint with a simple, safe, orally administered intervention. Its mechanism — gut mucosal symbiosis — is entirely orthogonal to all pharmacological approaches, and the initial Akkermansia abundance correlation with cardiometabolic response hints at a precision nutrition angle. The implementation pathway is faster than a drug (supplement regulation), the safety profile appears clean, and the intervention is conceptually accessible to a broad population. The 24-week window and industry COI are meaningful limitations, but the design is sound.
Why it matters: A daily bacterial supplement — not a drug — can halve the weight regain after dieting, opening a new class of microbiome-based obesity tools with potentially broad accessibility.
🥉 Rank 3 — Peripheral UWF DR prediction (Impact: 7.10) This prospective 2-year longitudinal study in 528 diabetic eyes demonstrates that AI-quantified peripheral retinal haemorrhage density and predominantly peripheral lesions independently predict diabetic retinopathy progression — and UWF imaging and AI quantification tools already exist in many clinical settings. With 537 million people with diabetes globally and DR the leading preventable cause of blindness, even incremental improvements in risk stratification have enormous population-level impact. The study is prospective, uses validated endpoints, and is near-term implementable with existing technology.
Why it matters: By measuring what happens at the edges of the retina — regions conventional imaging often misses — clinicians could identify which diabetic patients are headed for vision loss years earlier, when intervention is still most effective.
Rank 4 (tied) — NUP98r AML, Feladilimab (negative), BTKi vs VenR CLL, ELSA caring cognition (Impact: 5.90) These four articles tie on composite score, each with distinct value propositions. NUP98r AML provides the largest adult cohort yet with actionable FLT3i guidance. The feladilimab negative RCT immediately redirects clinical and research resources away from ICOS monotherapy in post-checkpoint NSCLC. The Czech CLL real-world analysis gives practicing oncologists the first direct comparison of two standard options. ELSA's 19-year matched cohort data on carer cognitive trajectories is methodologically outstanding and policy-relevant.
Rank 5 — BRAT1/INTS11 U1 snRNA biomarker (Impact: 6.30) Ranked separately from the tied group because its scientific novelty (9/10) and evidence quality (7/10) are exceptional within its disease context. While Population Reach is inherently low for an ultra-rare disease, the unmet diagnostic need is profound — families currently receiving VUS-level BRAT1 diagnoses gain a quantitative, functionally grounded reclassification tool immediately from this work. The Genome Medicine publication, multi-institutional cohort, and zebrafish orthogonal validation all strengthen confidence. Scored lower in the composite only because the weighted formula penalizes rare-disease population reach, not because the science is weak.
Why it matters: For the handful of families worldwide living with BRAT1-related disease, this finding transforms an uncertain genetic variant into a measurable, severity-correlated molecular diagnosis.